Cullinan Oncology Appoints Jeff Trigilio as Chief Financial Officer Cullinan Oncology Appoints Jeff Trigilio as Chief Financial Officer root2020-11-13T10:09:14-05:00October 29, 2020| Read More
Cullinan Oncology, German Cancer Research Center (DKFZ) and the University of Tübingen Announce the Formation of Cullinan Florentine to Develop CLN-049, a Novel Bispecific Antibody for AML Cullinan Oncology, German Cancer Research Center (DKFZ) and the University of Tübingen Announce the Formation of Cullinan Florentine to Develop CLN-049, a Novel Bispecific Antibody for AML root2020-09-15T07:30:14-05:00September 15, 2020| Read More
Cullinan Oncology Launches Cullinan Amber to Pioneer Next-Generation Cytokine Fusion Proteins for Cancer Therapy Cullinan Oncology Launches Cullinan Amber to Pioneer Next-Generation Cytokine Fusion Proteins for Cancer Therapy root2020-07-22T17:52:30-05:00July 22, 2020| Read More
Cullinan Oncology and PDI Therapeutics Join Forces to Bring Novel, First-In-Class Immuno-Oncology Antibody into the Clinic through a $26M Series A Financing Cullinan Oncology and PDI Therapeutics Join Forces to Bring Novel, First-In-Class Immuno-Oncology Antibody into the Clinic through a $26M Series A Financing root2020-06-11T11:36:55-05:00June 11, 2020| Read More
Cullinan Oncology Completes $98.5 Million Series B Financing Cullinan Oncology Completes $98.5 Million Series B Financing root2020-06-03T16:12:17-05:00June 3, 2020| Read More
Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, a Novel EGFR Tyrosine Kinase Inhibitor Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, a Novel EGFR Tyrosine Kinase Inhibitor root2019-02-05T18:07:22-05:00February 5, 2019| Read More
Cullinan Oncology Secures $150 Million Series A Financing To Build Innovative Development Company Cullinan Oncology Secures $150 Million Series A Financing To Build Innovative Development Company root2017-11-08T10:54:46-05:00October 3, 2017| Read More
